Skip to main content
logo
Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.770
-0.015 (-0.84%)
Aug 5, 2026, 4:00 PM EDT - Market closed

Innate Pharma Cash Flow Statement

Millions EUR. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-49.18-49.47-7.57-58.1-52.81
Depreciation & Amortization
1.381.995.0945.414.6
Stock-Based Compensation
2.573.944.264.252.62
Other Adjustments
3.1-2.53-2.241.8-3.29
Changes in Other Operating Activities
----12.5-9.89
Operating Cash Flow
-52.76-6.9-32.56-19.16-58.46
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-0.14-0.39-0.35-0.54-0.93
Sale of Property, Plant & Equipment
0.01-0.22-0.05
Purchases of Intangible Assets
---2-0.59-0.4
Purchases of Investments
---0-0-0
Proceeds from Sale of Investments
7.049.5922.7725.77-
Other Investing Activities
0.39---0.37
Investing Cash Flow
7.299.220.631.88-0.92

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
----28.7
Long-Term Debt Repaid
-8.91-8.94-2.36-2.03-2.07
Net Long-Term Debt Issued (Repaid)
-8.91-8.94-2.36-2.0326.63
Issuance of Common Stock
14.982.930.40.20.5
Net Common Stock Issued (Repurchased)
14.982.930.40.20.5
Financing Cash Flow
6.07-6.01-1.97-1.8326.82

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
1.09-0.510.27-0.43-0.48
Net Cash Flow
-38.3-4.21-13.62-19.53-33.04

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-52.9-7.29-32.91-19.69-59.39
Free Cash Flow Growth
-----
FCF Margin
-587.40%-36.22%-53.39%-34.14%-240.40%
Free Cash Flow Per Share
-0.59-0.09-0.41-0.25-0.75
Levered Free Cash Flow
-56.84-56.8-5.19-27.76-32.4
Unlevered Free Cash Flow
-52.76-49.97-7.93-25.06-54.04
SEC Filings: 10-K · 10-Q